{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:51:04Z","timestamp":1775872264422,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["aap.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Adv Periodontics"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Medication\u2010related osteonecrosis of the jaw (MRONJ) is a recognized complication of intravenous (IV) bisphosphonate therapy, particularly following invasive dental procedures such as extractions or implant placement. Although the risk of MRONJ decreases after discontinuation of therapy, prolonged skeletal retention of bisphosphonates necessitates careful long\u2010term evaluation and surgical planning.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n An American Society of Anesthesiologists (ASA) (II 72\u2010year\u2010old male with history of high\u2010dose IV pamidronate therapy for multiple myeloma (last dose 11 years prior) presented for implant placement at tooth #18. Clinical and radiographic examination revealed a vertical root fracture with associated periapical pathology. The tooth was extracted, and ridge preservation was performed. Three and half months later, implant placement followed with the use of preoperative antibiotic prophylaxis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Five months post\u2010implant placement, the patient developed a lesion on the lingual vestibular aspect of site #18, characterized by purulence, bleeding, and exposed necrotic bone measuring approximately 10 \u00d7 2\u00a0mm, without radiographic appearance. Histopathologic evaluation confirmed MRONJ. The lesion was treated with conservative surgical debridement, followed by 0.12% chlorhexidine gluconate rinses twice daily for 2 weeks. Healing was allowed by secondary intention without sutures, and postoperative systemic antibiotic therapy was prescribed. Follow\u2010up examinations at 2 and 4 weeks demonstrated complete clinical healing, with no recurrence observed at 6 months.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The risk of MRONJ may persist for more than 11 years after cessation of high\u2010dose IV bisphosphonate therapy. The development of MRONJ, despite a C\u2010terminal telopeptide (CTX) value traditionally considered favorable, underscores the limited predictive utility of CTX testing. Accordingly, management decisions should be guided by comprehensive clinical assessment and interdisciplinary communication rather than reliance on biochemical markers alone.<\/jats:p>\n <\/jats:sec>\n \n Key Points\/Highlights<\/jats:title>\n \n Why is this case new information\n \n \n This case reports stage 2 medication\u2010related osteonecrosis of the jaw (MRONJ) occurring 11 years after high\u2010dose intravenous (IV) pamidronate cessation following extraction, ridge preservation, and implant placement, illustrating very late\u2010onset disease that can arise adjacent to the surgical site, highlighting the limitations of serum C\u2010terminal telopeptide testing, and emphasizing the need for long\u2010term clinical vigilance and cautious surgical planning in patients with a remote history of bisphosphonate therapy.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n \n What are the keys to successful management of this case?\n \n \n Successful management relied on thorough risk assessment, informed consent, atraumatic surgery with antibiotic prophylaxis, early detection and conservative stage 2 MRONJ treatment, histopathologic confirmation, healing by secondary intention with antiseptics and short\u2010term antibiotics, and coordinated interdisciplinary care.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n \n What are the primary limitations to the success of this case?\n \n \n Limitations stem from the patient's history of high\u2010dose IV bisphosphonate therapy, the unpredictable long\u2010term risk of MRONJ, the lack of reliable biomarkers or imaging for risk prediction, multifactorial pathogenesis including local and systemic factors, and the potential for late recurrence despite initial successful management.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Plain language summary<\/jats:title>\n This report describes a patient who developed a rare complication of long\u2010term bisphosphonate therapy, a medication commonly used to treat bone diseases such as multiple myeloma. Eleven years after receiving high\u2010dose intravenous bisphosphonates, the patient underwent tooth extraction and dental implant placement, initially healing without problems. Several months later, a small area of exposed, infected bone appeared near the implant, which was diagnosed as medication\u2010related osteonecrosis of the jaw (MRONJ). The condition was successfully treated with careful surgical cleaning, local antiseptic rinses, short\u2010term antibiotics, and close monitoring, without the need to remove the implant. This case is important because it shows that MRONJ can occur more than a decade after stopping bisphosphonate therapy, even when routine blood tests suggest low risk. It also demonstrates that the disease can appear near, rather than exactly at, the surgical site. The report emphasizes the need for thorough risk assessment, careful surgical planning, prompt recognition of complications, and collaboration among dental and medical specialists. Overall, it highlights that patients with a remote history of high\u2010dose bisphosphonates require long\u2010term vigilance and individualized care when undergoing dental procedures.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cap.70056","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:05:16Z","timestamp":1774274716000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Late\u2010onset medication\u2010related osteonecrosis of the jaw 11 years after IV bisphosphonates following implant placement"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2821-7063","authenticated-orcid":false,"given":"Nikolaos","family":"Soldatos","sequence":"first","affiliation":[{"name":"Division of Periodontology Department of Regenerative and Reconstructive Sciences School of Dentistry Oregon Health & Science University Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Chandra","sequence":"additional","affiliation":[{"name":"Division of Oral Diagnostic Sciences Department of Oral and Craniofacial Sciences School of Dentistry Oregon Health & Science University Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0658-2924","authenticated-orcid":false,"given":"Hongseok","family":"An","sequence":"additional","affiliation":[{"name":"Division of Restorative Dentistry Department of Oral Rehabilitation and Biosciences School of Dentistry Oregon Health & Science University Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Melakopoulos","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery Hygeia Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Weltman","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences School of Dental Medicine University of Nevada Las Vegas Las Vegas Nevada USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01186"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2022.02.008"},{"key":"e_1_2_10_4_1","first-page":"63","article-title":"The prevention of medication\u2011related osteonecrosis of the jaw","volume":"114","author":"Poxleitner P","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias A","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.joms.2014.08.017","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication\u2011related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero SL","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan AA","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"3","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-051X.1975.tb01734.x","article-title":"Periodontal treatment of multirooted teeth. Results after 5 years","volume":"2","author":"Hamp SE","year":"1975","journal-title":"J Clin Periodontol"},{"issue":"12","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate\u2011induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx RE","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"6","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell RG","year":"2008","journal-title":"Osteoporos Int"},{"issue":"6","key":"e_1_2_10_11_1","first-page":"664","article-title":"Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis\u2014a position paper of SBEM, Sobep, and Abrasso","volume":"64","author":"Madeira M","year":"2020","journal-title":"Arch Endocrinol Metab"},{"issue":"9","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake MT","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen T","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","article-title":"Bisphosphonate\u2011related osteonecrosis of the jaws\u2014a review","volume":"48","author":"K\u00fchl S","year":"2012","journal-title":"Oral Oncol"},{"issue":"4","key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long\u2011term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts NB","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11420-015-9469-1","article-title":"Bisphosphonate treatment in osteoporosis: optimal duration of therapy and the incorporation of a drug holiday","volume":"12","author":"Villa JC","year":"2016","journal-title":"HSS J"},{"issue":"2","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin JH","year":"1996","journal-title":"Bone"},{"issue":"1","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5125\/jkaoms.2020.46.1.78","article-title":"The effect of bisphosphonate discontinuation on the incidence of postoperative medication\u2011related osteonecrosis of the jaw after tooth extraction","volume":"46","author":"Kang SH","year":"2020","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"issue":"3","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.sdentj.2022.01.003","article-title":"Medication\u2011related osteonecrosis of the jaw (MRONJ): a review of pathophysiology, risk factors, preventive measures and treatment strategies","volume":"34","author":"AlRowis R","year":"2022","journal-title":"Saudi Dent J"},{"issue":"9","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.3390\/ijms24097948","article-title":"Immune dysfunction in medication\u2011related osteonecrosis of the jaw","volume":"24","author":"Roato I","year":"2023","journal-title":"Int J Mol Sci"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.606043","article-title":"The role of the immune response in the development of medication\u2011related osteonecrosis of the jaw","volume":"12","author":"Zhang W","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","DOI":"10.1002\/dvg.23500","article-title":"Medication\u2011related osteonecrosis of the jaw: a literature review and update","volume":"60","author":"Kuroshima S","year":"2022","journal-title":"Genesis"},{"issue":"1","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/JPER.21-0611","article-title":"Association between periodontal disease, tooth extraction, and medication\u2011related osteonecrosis of the jaw in women receiving bisphosphonates: a national cohort\u2011based study","volume":"94","author":"Kwoen MJ","year":"2023","journal-title":"J Periodontol"},{"issue":"7","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.3390\/ijerph20075402","article-title":"Potential relationship between poor oral hygiene and MRONJ: an observational retrospective study","volume":"20","author":"D'Agostino S","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12090205"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113747"},{"issue":"1","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-02225-2","article-title":"Incidence of medication\u2011related osteonecrosis of the jaw and associated antiresorptive drugs in the adult Finnish population","volume":"15","author":"Kujanp\u00e4\u00e4 M","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10354-016-0437-2","article-title":"Position paper on medication\u2011related osteonecrosis of the jaw (MRONJ) [Positions papier zur medikamentenassoziierten Osteonekrose des Kiefers (MRONJ)] (in German)","volume":"166","author":"Svejda B","year":"2016","journal-title":"Wien Med Wochenschr"},{"issue":"3","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini M","year":"2023","journal-title":"Endocr Rev"},{"issue":"4","key":"e_1_2_10_30_1","first-page":"579","article-title":"Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from ESCEO, IOF, and IFCC","volume":"36","author":"Bhattoa HP","year":"2025","journal-title":"Osteoporos Int"},{"issue":"1","key":"e_1_2_10_31_1","first-page":"7","article-title":"Clinical use of bone markers: a challenge to variability","volume":"5","author":"Filella X","year":"2023","journal-title":"Adv Lab Med"},{"issue":"4","key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.11005\/jbm.2019.26.4.213","article-title":"Position statement on the use of bone turnover markers for osteoporosis treatment","volume":"26","author":"Park SY","year":"2019","journal-title":"J Bone Metab"},{"key":"e_1_2_10_33_1","first-page":"21","article-title":"Value of pre\u2011operative CTX serum levels in the prediction of medication\u2011related osteonecrosis of the jaw (MRONJ): a retrospective clinical study","volume":"10","author":"Salgueiro M","year":"2019","journal-title":"EMPA J"},{"issue":"5","key":"e_1_2_10_34_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0318260","article-title":"Identifying a predictive level of serum C\u2011terminal telopeptide associated with a low risk of medication\u2011related osteonecrosis of the jaw secondary to oral surgery: a systematic review and meta\u2011analysis","volume":"20","author":"Ghio C","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"e_1_2_10_35_1","first-page":"e26","article-title":"Biomarkers to predict the onset of bisphosphonate\u2010related osteonecrosis of the jaw: a systematic review","volume":"24","author":"Lorenzo\u2010Pouso AI","year":"2019","journal-title":"Med Oral Pathol Oral Cir Bucal"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.3390\/ijms24108635","article-title":"Identification of potential biomarkers and small\u2010molecule drugs for bisphosphonate\u2010related osteonecrosis of the jaw: an integrated bioinformatics study using big data","volume":"24","author":"Balachandran K","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"e_1_2_10_37_1","first-page":"29","article-title":"Clinical and histologic evaluation of bone\u2011replacement grafts in the treatment of localized alveolar ridge defects. Part 1: Mineralized freeze\u2011dried bone allograft","volume":"23","author":"Feuille F","year":"2003","journal-title":"Int J Periodont Restorative Dent"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/biomedicines13051042","article-title":"Photobiomodulation in medication\u2010related osteonecrosis of the jaw: outcomes in stage I and its adjunctive role in advanced cases","volume":"13","author":"Michalak F","year":"2025","journal-title":"Biomedicines"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/prd.12608","article-title":"Autologous platelet concentrates as an adjuvant in the surgical management of medication\u2010related osteonecrosis of the jaw","volume":"97","author":"Bennardo F","year":"2025","journal-title":"Periodontol 2000"},{"key":"e_1_2_10_40_1","article-title":"The pentoxifylline and tocopherol protocol and its use in the management of osteoradionecrosis of the jaws: a scoping review","author":"Carreiro RT","year":"2025","journal-title":"J Am Dent Assoc"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","DOI":"10.1177\/01455613251381176","article-title":"A comprehensive review of the PENTOCLO protocol and its applications in the head and neck","author":"Ringerbach S","year":"2025","journal-title":"Ear Nose Throat J"}],"container-title":["Clinical Advances in Periodontics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aap.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cap.70056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aap.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cap.70056","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aap.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cap.70056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T14:05:21Z","timestamp":1774274721000},"score":1,"resource":{"primary":{"URL":"https:\/\/aap.onlinelibrary.wiley.com\/doi\/10.1002\/cap.70056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":40,"alternative-id":["10.1002\/cap.70056"],"URL":"https:\/\/doi.org\/10.1002\/cap.70056","archive":["Portico"],"relation":{},"ISSN":["2573-8046","2163-0097"],"issn-type":[{"value":"2573-8046","type":"print"},{"value":"2163-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"2026-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cap.70056"}}